Literature DB >> 9588558

Telomerase activity in human gliomas.

S Le1, J J Zhu, D C Anthony, C W Greider, P M Black.   

Abstract

OBJECTIVE: Telomerase activity, which is undetectable in most mature normal tissues, has been identified in many types of human cancers, including neuroblastomas and oligodendrogliomas. These findings suggest that a novel mechanism in addition to activation of oncogenes and inactivation of tumor suppressor genes may play an important role in tumorigenesis. The goal of the present study was to assess and correlate the telomerase activity in astrocytic gliomas of different grades.
METHODS: Telomere repeat amplification protocol and Southern blot hybridization with telomere-specific probes were used to detect telomerase activity and to measure terminal restriction fragment length, respectively.
RESULTS: Telomerase activity was detected in 3 of 9 (33%) low-grade astrocytomas (World Health Organization Grade II), 5 of 11 (45%) anaplastic astrocytomas (World Health Organization Grade III), 36 of 41 (89%) glioblastomas multiforme (World Health Organization Grade IV), 3 of 4 (75%) oligodendrogliomas, and none of 4 normal brain specimens.
CONCLUSION: We demonstrated that telomerase activity is absent in normal brain tissues while present in most glioma samples (72%). The frequency of such activity increases with malignancy. These results suggest that telomerase activity may be used as a tumor marker and that the activation of telomerase may correlate with initiation and malignant progression of astrocytic tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588558     DOI: 10.1097/00006123-199805000-00099

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  20 in total

1.  Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.

Authors:  Hideaki Ito; Takao Kanzawa; Toru Miyoshi; Satoshi Hirohata; Satoru Kyo; Arifumi Iwamaru; Hiroshi Aoki; Yasuko Kondo; Seiji Kondo
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

2.  Local interstitial delivery of z-butylidenephthalide by polymer wafers against malignant human gliomas.

Authors:  Horng-Jyh Harn; Shinn-Zong Lin; Po-Cheng Lin; Cyong-Yue Liu; Po-Yen Liu; Li-Fu Chang; Ssu-Yin Yen; Dean-Kuo Hsieh; Fu-Chen Liu; Dar-Fu Tai; Tzyy-Wen Chiou
Journal:  Neuro Oncol       Date:  2011-05-12       Impact factor: 12.300

3.  Correlation of clinical features and telomerase activity in human gliomas.

Authors:  F Huang; H Kanno; I Yamamoto; Y Lin; Y Kubota
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

Review 4.  A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option.

Authors:  Asa Peterson; Amy Bansal; Florence Hofman; Thomas C Chen; Gabriel Zada
Journal:  J Neurooncol       Date:  2014-01-08       Impact factor: 4.130

5.  MMP-9 silencing regulates hTERT expression via β1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells.

Authors:  Shivani Ponnala; Chandramu Chetty; Krishna Kumar Veeravalli; Dzung H Dinh; Jeffrey D Klopfenstein; Jasti S Rao
Journal:  Cell Signal       Date:  2011-08-09       Impact factor: 4.315

6.  RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells.

Authors:  Ch Lavanya; M K Sibin; M M Srinivas Bharath; M Jeru Manoj; Manjunatha M Venkataswamy; Dhananjaya I Bhat; K V L Narasinga Rao; G K Chetan
Journal:  Cytotechnology       Date:  2016-10-18       Impact factor: 2.058

7.  New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.

Authors:  Rintaro Hashizume; Tomoko Ozawa; Sergei M Gryaznov; Andrew W Bollen; Kathleen R Lamborn; William H Frey; Dennis F Deen
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

8.  Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.

Authors:  Tomoko Ozawa; Sergei M Gryaznov; Lily J Hu; Krisztina Pongracz; Raquel A Santos; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

9.  Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

Authors:  Daniela Lötsch; Bahil Ghanim; Magdalena Laaber; Gabriele Wurm; Serge Weis; Stefan Lenz; Gerald Webersinke; Josef Pichler; Walter Berger; Sabine Spiegl-Kreinecker
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

10.  Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.

Authors:  Atsuo Yoshino; Yoichi Katayama; Takao Fukushima; Takao Watanabe; Chiaki Komine; Takakazu Yokoyama; Kaoru Kusama; Itaru Moro
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.